Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Dow
Mallinckrodt
Boehringer Ingelheim
McKinsey

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR ICOSAPENT ETHYL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Icosapent Ethyl

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01492361 ↗ A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Completed Amarin Pharma Inc. Phase 3 2011-11-01 AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) being developed by Amarin Pharma Inc. for the treatment of cardiovascular disease in statin-treated patients with hypertriglyceridemia. The purpose of this study is to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.
NCT02113163 ↗ PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA Unknown status Thetis Pharmaceuticals LLC Phase 1 2014-03-01 The primary objective of the study is to contrast the pharmacokinetic profiles of metformin and EPA delivered separately as co-administered products (metformin hydrochloride or Glucophage and icosapent ethyl or Vascepa) and together as the solid dose form (metformin eicosapentaenoate or TP-101) under fasted and fed conditions. A secondary objective is to evaluate the safety and tolerability of single and repeat single doses of TP-101.
NCT02719327 ↗ Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid Active, not recruiting University of Wisconsin, Madison Phase 2/Phase 3 2017-06-08 The number of Americans diagnosed with Alzheimer's disease (AD) is expected to triple by 2050. Compared to the general population, Veterans have a greater risk of AD, likely in part due to their increased incidence of traumatic brain injury, post-traumatic stress disorder, depression, and other vascular-related health issues. Based on available data, 423,000 new cases of AD are anticipated in Veterans by 2020. Thus, the discovery of effective therapies to prevent or delay the onset of AD in Veterans is critical. The goal of this study is to evaluate the efficacy of a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) called icosapent ethyl (IPE), on improving brain blood flow, spinal fluid markers of AD pathology, and cognitive performance in middle-aged, cognitively-healthy Veterans with increased risk of AD. If IPE delays the onset of AD by even 5 years, the incidence of AD would be reduced by 50% in this population and could have a profound effect on Veteran quality of life and healthcare costs.
NCT02719327 ↗ Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid Active, not recruiting VA Office of Research and Development Phase 2/Phase 3 2017-06-08 The number of Americans diagnosed with Alzheimer's disease (AD) is expected to triple by 2050. Compared to the general population, Veterans have a greater risk of AD, likely in part due to their increased incidence of traumatic brain injury, post-traumatic stress disorder, depression, and other vascular-related health issues. Based on available data, 423,000 new cases of AD are anticipated in Veterans by 2020. Thus, the discovery of effective therapies to prevent or delay the onset of AD in Veterans is critical. The goal of this study is to evaluate the efficacy of a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) called icosapent ethyl (IPE), on improving brain blood flow, spinal fluid markers of AD pathology, and cognitive performance in middle-aged, cognitively-healthy Veterans with increased risk of AD. If IPE delays the onset of AD by even 5 years, the incidence of AD would be reduced by 50% in this population and could have a profound effect on Veteran quality of life and healthcare costs.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Icosapent Ethyl

Condition Name

Condition Name for Icosapent Ethyl
Intervention Trials
Hypertriglyceridemia 4
Cardiovascular Diseases 3
Covid19 2
Eicosapentaenoic Acid 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Icosapent Ethyl
Intervention Trials
Hypertriglyceridemia 6
Colorectal Neoplasms 4
Cardiovascular Diseases 3
Diabetes Mellitus, Type 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Icosapent Ethyl

Trials by Country

Trials by Country for Icosapent Ethyl
Location Trials
United States 56
Canada 7
India 6
Australia 6
South Africa 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Icosapent Ethyl
Location Trials
Massachusetts 4
Kentucky 2
Indiana 2
Illinois 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Icosapent Ethyl

Clinical Trial Phase

Clinical Trial Phase for Icosapent Ethyl
Clinical Trial Phase Trials
Phase 4 2
Phase 3 5
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Icosapent Ethyl
Clinical Trial Phase Trials
Recruiting 7
Completed 5
Active, not recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Icosapent Ethyl

Sponsor Name

Sponsor Name for Icosapent Ethyl
Sponsor Trials
Amarin Pharma Inc. 4
National Cancer Institute (NCI) 2
Massachusetts General Hospital 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Icosapent Ethyl
Sponsor Trials
Other 25
Industry 10
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.